Cytokines & Chemokines

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Recently, the new B.1.1.529 variant was confirmed in South Africa and preliminary evidence suggests an increased risk of reinfection with this variant. The B.1.1.529 variant was first reported to WHO on 24 November 2021 and WHO has designated this variant as a VOC (Variant of Concern), named Omicron. There are more than 30 mutations in the spike protein.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Recently, the new B.1.1.529 variant was confirmed in South Africa and preliminary evidence suggests an increased risk of reinfection with this variant. The B.1.1.529 variant was first reported to WHO on 24 November 2021 and WHO has designated this variant as a VOC (Variant of Concern), named Omicron. There are more than 30 mutations in the spike protein.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease 2019 (COVID-19). Nucleocapsid Protein is the most abundant structural protein of the coronavirus which is associated with the nucleic acid. The sublineage B.1.617.2 has been redesignated as a "variant of concern" (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease 2019 (COVID-19). Nucleocapsid Protein is the most abundant structural protein of the coronavirus which is associated with the nucleic acid. The sublineage B.1.617.2 has been redesignated as a "variant of concern" (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.

BA.2 differs from BA.1 in its genetic sequence, including some amino acid differences in the spike protein and other proteins. Studies have shown that BA.2 has a growth advantage over BA.1. Studies are ongoing to understand the reasons for this growth advantage, but initial data suggest that BA.2 appears inherently more transmissible than BA.1, which currently remains the most common Omicron sublineage reported. This difference in transmissibility appears to be much smaller than, for example, the difference between BA.1 and Delta. Further, although BA.2 sequences are increasing in proportion relative to other Omicron sublineages (BA.1 and BA.1.1), there is still a reported decline in overall cases globally.

BA.2 differs from BA.1 in its genetic sequence, including some amino acid differences in the spike protein and other proteins. Studies have shown that BA.2 has a growth advantage over BA.1. Studies are ongoing to understand the reasons for this growth advantage, but initial data suggest that BA.2 appears inherently more transmissible than BA.1, which currently remains the most common Omicron sublineage reported. This difference in transmissibility appears to be much smaller than, for example, the difference between BA.1 and Delta. Further, although BA.2 sequences are increasing in proportion relative to other Omicron sublineages (BA.1 and BA.1.1), there is still a reported decline in overall cases globally.

Human recombinant IL-2 (aa 21-153(end)), Genbank accession # NM_000586, with a C-terminal Fc-Avi-Tag was expressed in HEK293 cells.

Human recombinant IL-2 (aa 21-153(end)), Genbank accession # NM_000586, with a C-terminal Fc-Avi-Tag was expressed in HEK293 cells.

Recombinant human CD93, also known as complement component C1q receptor, encompassing amino acids 24-580. The C-terminus is fused with the Fc fragment of a human IgG1 followed by an Avi-Tag™. The recombinant protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.